Efficacy and Safety of Incretin-Based Therapies in Patients with Type 2 Diabetes Mellitus

被引：34

作者：

Gilbert, Matthew P. ^{[1
]}

Pratley, Richard E. ^{[1
]}

机构：

[1] Univ Vermont, Diabet & Metab Translat Med Unit, Coll Med, Burlington, VT 05405 USA

来源：

AMERICAN JOURNAL OF MEDICINE | 2009年 / 122卷 / 06期

关键词：

DPP-4; exenatide-LAR; GLP-1 receptor agonist; liraglutide; sitagliptin; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; IMPROVES GLYCEMIC CONTROL; INITIAL COMBINATION THERAPY; DRUG-NAIVE PATIENTS; EXENATIDE EXENDIN-4; GLUCOSE CONTROL; INSULIN GLARGINE; RANDOMIZED-TRIAL; PEPTIDE-1; ANALOG; TREATED PATIENTS;

D O I：

10.1016/j.amjmed.2009.03.013

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This article aims to provide an overview of efficacy and safety data on glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors in the treatment of type 2 diabetes mellitus. Our goal is to differentiate the clinical profiles of GLP-1 receptor agonists and DPP-4 inhibitors, as well as the individual agents within each class. Additionally, we examine the utility of GLP-1 receptor agonists and DPP-4 inhibitors as these agents may be applied at different stages of type 2 diabetes therapy and discuss recently published clinical findings and their implications for treatment. (c) 2009 Elsevier Inc. All rights reserved. The American Journal of Medicine (2009) 122, S11-S24

引用

页码：11 / 24

页数：14

共 47 条

[1] The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men [J].

Agerso, H ;

Jensen, LB ;

Elbrond, B ;

Rolan, P ;

Zdravkovic, M .

DIABETOLOGIA, 2002, 45 (02) :195-202

[2]

*AM PHARM E LILL C, 2007, IMP PRESCR INF HEALT

[3]

*AM PHARM INC, 2007, BYETT EX INJ PACK IN

[4] Efficacy and safety of incretin therapy in type 2 diabetes - Systematic review and meta-analysis [J].

Amori, Renee E. ;

Lau, Joseph ;

Pittas, Anastassios G. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (02) :194-206

[5]

[Anonymous], 2007, JAN SIT PACK INS

[6]

[Anonymous], DIABETES CARE 0316

[7] Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes [J].

Aschner, Pablo ;

Kipnes, Mark S. ;

Lunceford, Jared K. ;

Sanchez, Matilde ;

Mickel, Carolyn ;

Williams-Herman, Debora E. .

DIABETES CARE, 2006, 29 (12) :2632-2637

[8] Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin [J].

Bosi, Emanuele ;

Camisasca, Riccardo Paolo ;

Collober, Carole ;

Rochotte, Erika ;

Garber, Alan J. .

DIABETES CARE, 2007, 30 (04) :890-895

[9] Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes [J].

Buse, JB ;

Henry, RR ;

Han, J ;

Kim, DD ;

Fineman, MS ;

Baron, AD .

DIABETES CARE, 2004, 27 (11) :2628-2635

[10] Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone [J].

Charbonnel, Bernard ;

Karasik, Avraham ;

Liu, Ji ;

Wu, Mei ;

Meininger, Gary .

DIABETES CARE, 2006, 29 (12) :2638-2643

← 1 2 3 4 5 →